A study of QY201 tablets for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new pill called QY201 for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. It aims to see if QY201 can help control itching and skin inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had eczema for at least 1 year, and it must be moderate to severe now.
- Your eczema must have not gotten better with prescription creams or you needed stronger pills or shots in the past 6 months.
- You need to be willing to use a plain moisturizer at least twice a day.
- You must agree to use effective birth control or not plan pregnancy for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
This trial tests a new medication called ARQ-234 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study looks at how the body handles single and multiple doses, and if it can help treat eczema.
This study tests a new cream called JYP0066 for people with mild-to-moderate atopic dermatitis (eczema). It aims to see if the cream safely reduces itching and skin inflammation. It might help if you have tried other creams and still have symptoms.
This study tests an oral medication (TLL-018) for people with moderate-to-severe atopic dermatitis (eczema) that hasn't been helped enough by topical treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.